Emergent BioSolutions | EBS - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Akebia Therapeutics USD 32.61M 8.98M 2025-12
ALKERMES USD 1.82B 85.86M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amarin USD 459.28M 387K 2025-12
ANI Pharmaceuticals USD 540.72M 34.91M 2025-12
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Coherus Biosciences USD 61.01M 26.76M 2025-12
Emergent BioSolutions USD 649.3M 47.9M 2023-12
Exelixis USD 2.16B 619K 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Ironwood Pharmaceuticals USD -264.16M 44M 2025-09
Lexicon Pharmaceuticals USD 107.54M 12.62M 2025-12
Lonza CHF 9.13B 513M 2025-12
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Myriad Genetics USD 368M 4.8M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Pacira USD 693.11M 34.1M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Sanofi EUR 71.71B 1.55B 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
United Therapeutics USD 7.1B 506M 2025-12
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Xoma USD 87.94M 15.5M 2025-09